AMRN - Amarin Corporation plc
19.09 +0.33 (1.76%)
After hours: 7:58PM EDT
| Previous Close | 19.01 |
| Open | 19.00 |
| Bid | 19.05 x 2900 |
| Ask | 19.09 x 1400 |
| Day's Range | 18.37 - 19.10 |
| 52 Week Range | 2.35 - 23.34 |
| Volume | 5,181,554 |
| Avg. Volume | 8,399,300 |
| Market Cap | 6.178B |
| Beta (3Y Monthly) | 0.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.39 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.00 |
- GlobeNewswire•4 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline – AMRN
Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ: AMRN) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and indexed under 19-cv-08423, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Amarin Corporation plc (“Amarin” or the “Company”) between September 24, 2018 and November 9, 2018 (the “Class Period”), who were damaged thereby seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”). If you are a shareholder who purchased Amarin securities between September 24, 2018, and November 9, 2018, both dates inclusive, you have until April 23, 2019, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980.
- ACCESSWIRE•4 hours ago
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 21, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amarin Corporation plc (''Amarin'' ...
- ACCESSWIRE•11 hours ago
SHAREHOLDER ALERT: ZIV DPLO AMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / March 21, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you ...
- GlobeNewswire•yesterday
APRIL 23 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Amarin Corporation plc – AMRN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Amarin Corporation plc (AMRN) from September 24, 2018 through November 9, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Amarin investors under the federal securities laws. If you wish to serve as lead plaintiff, you must move the Court no later than April 23, 2019.
- GlobeNewswire•yesterday
Class Action AKRX, AMRN & CAG Bronstein, Gewirtz & Grossman, LLC Update
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq.
- GlobeNewswire•yesterday
SHAREHOLDER ALERT: MHLD AMRN INGN USX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, March 20, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- ACCESSWIRE•yesterday
Bronstein, Gewirtz & Grossman, LLC Class Action Update AKRX, AMRN & CAG
NEW YORK, NY / ACCESSWIRE / March 20, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
- ACCESSWIRE•2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation plc of Class Action Lawsuit and Upcoming Deadline – AMRN
NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc (''Amarin'' or the ''Company'') (AMRN) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and indexed under 19-cv-08423, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired the publicly traded securities of Amarin Corporation plc (''Amarin'' or the ''Company'') between September 24, 2018 and November 9, 2018 (the ''Class Period''), who were damaged thereby seeking to pursue remedies under the Securities Exchange Act of 1934 (the ''Exchange Act''). If you are a shareholder who purchased Amarin securities between September 24, 2018 and November 9, 2018, both dates inclusive, you have until April 23, 2019, to ask the Court to appoint you as Lead Plaintiff for the class.
- GlobeNewswire•2 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VALE, SVXY, AMRN and NIO
NEW YORK, March 19, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•2 days ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Amarin stock or options between September 24, 2018 and November 9, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/AMRN. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.
- GlobeNewswire•2 days ago
CLASS ACTION UPDATE for AMRN, CNDT, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, March 19, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- ACCESSWIRE•2 days ago
Class Action Update AKRX, AMRN & CAG Bronstein, Gewirtz & Grossman, LLC
NEW YORK, NY / ACCESSWIRE / March 19, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
CNW Group•3 days agoHLS Therapeutics Announces Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™
TORONTO , March 19, 2019 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (HLS.TO), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Amarin Corporation plc (AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa® (icosapent ethyl), the REDUCE-IT™ study, showing that Vascepa provided a statistically significant 30% risk reduction in total (first and subsequent) cardiovascular events compared to placebo in the statin-treated patient population studied in REDUCE-IT. HLS has in-licensed the exclusive rights to Vascepa for the Canadian market.
- CNW Group•3 days ago
HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease
HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease
- GlobeNewswire•3 days ago
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68th Annual Scientific Session
Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, in addition to its previously announced data from scientific presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session from March 16-18, 2019 in New Orleans, LA, announced data from three presented scientific posters. Poster data also delved into potential mechanisms of action for Vascepa® (icosapent ethyl) capsules. In a poster titled, “Triglycerides as a Risk Factor for Coronary Heart Disease: What Measure and What Cutoff?”, research focused on triglyceride levels of people who had their first cardiovascular event.
- GlobeNewswire•3 days ago
Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Levels
BEDMINSTER, N.J. and DUBLIN, Ireland, March 18, 2019 -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced.
- Benzinga•3 days ago
Amarin Reports Encouraging Data, Vascepa Shows 30% Reduction In Total Cardiovascular Events In REDUCE-IT Study
Amarin Corporation (NASDAQ: AMRN) presented data for its cardiovascular outcome study of its prescription Vascepa (icosapent ethyl), the REDUCE-IT study. Vascepa demonstrated a statistically significant 30 percent risk reduction in cardiovascular events compared to placebo in the statin-treated population in REDUCE-IT. Total events tracked in the study included a patient’s first and subsequent MACE occurrences.
- Reuters•4 days ago
Amarin's Vascepa cuts occurrence of serious heart problems 30 pct -study
A high dose of Amarin Corp's Omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according to data presented on Monday. Compared with a placebo, Vascepa cut the combined rate of heart attacks, strokes, heart-related death, need for artery-clearing procedures and hospitalizations for unstable angina by 30 percent in heart disease patients at high risk for such events. Amarin in September released initial results from the study of 8,179 patients already taking other heart drugs that showed a 25 percent reduction of serious heart events for those receiving a 4 gram dose of Vascepa compared with placebo, data that sent its share price surging from around $3 to over $12.
- PR Newswire•4 days ago
Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™
BEDMINSTER, N.J. and DUBLIN, March 18, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa® (icosapent ethyl), the REDUCE-IT™ study, showing that Vascepa provided a statistically significant 30% risk reduction in total (first and subsequent) cardiovascular events compared to placebo in the statin-treated patient population studied in REDUCE-IT.
- GlobeNewswire•4 days ago
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DBVT, AMRN, WTW and CRBP
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.
- Benzinga•6 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support. Here are some key catalysts that can move biotech stocks in the ...
- ACCESSWIRE•6 days ago
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SPB, BRS and AMRN
CEDARHURST, NY / ACCESSWIRE / March 15, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. ...